

Toripalimab (LOQTORZI) for Nasopharyngeal Carcinoma

Criteria for Use

September 2024

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at www.pbm.va.gov or [PBM INTRANet](#) for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive toripalimab.

- Autoimmune disease
- Immunosuppression requiring a corticosteroid equivalent to >10 mg per day of prednisone
- Primary immunodeficiency
- History of allogeneic hematopoietic stem cell or solid organ transplant
- Pregnancy
- Lactating

Inclusion Criteria

The following criteria must be met.

- Indication is FDA-approved

Additional Inclusion Criteria All of the following must be fulfilled

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria Select if applicable

- Female patients of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for 4 months after the last dose.
- Male patients with female partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for 4 months after the last dose.

Other Justification

Prepared 9/2024. Contact: Berni Heron, Pharm.D., BCOP National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services